{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:41:27Z","timestamp":1790268087370,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":2279,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.14283\/jpad.2018.23","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T07:56:31Z","timestamp":1614326191000},"page":"171-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force"],"prefix":"10.1016","volume":"5","author":[{"given":"P.S.","family":"Aisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Siemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Michelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Doody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.14283\/jpad.2018.23_bib1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat Neurosci"},{"issue":"15","key":"10.14283\/jpad.2018.23_bib2","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5563","key":"10.14283\/jpad.2018.23_bib3","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"key":"10.14283\/jpad.2018.23_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2012.05.2187","article-title":"The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials","author":"Raghavan","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.14283\/jpad.2018.23_bib5","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"10.14283\/jpad.2018.23_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.14283\/jpad.2018.23_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2018.23_bib8","first-page":"8","article-title":"Delayed-start analyses in the Phase 3 solanezumab Expedition3 study in mild Alzheimer's disease","volume":"5","author":"Liu-Seifert","year":"2018","journal-title":"J Prev Alz Dis"},{"key":"10.14283\/jpad.2018.23_bib9","doi-asserted-by":"crossref","first-page":"P1452","DOI":"10.1016\/j.jalz.2017.07.506","article-title":"PET biomarkers in the Expedition 3 trial of patients with mild AD","volume":"13","author":"Mintun","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.14283\/jpad.2018.23_bib10","first-page":"116","article-title":"EU\/US\/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials","volume":"4","author":"Aisen","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2018.23_bib11","first-page":"3","article-title":"Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries","volume":"4","author":"Buckley","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"9","key":"10.14283\/jpad.2018.23_bib12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol"},{"issue":"363","key":"10.14283\/jpad.2018.23_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.14283\/jpad.2018.23_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1096\/fj.10-167213","article-title":"Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice","volume":"25","author":"Chang","year":"2011","journal-title":"FASEB J."},{"issue":"6","key":"10.14283\/jpad.2018.23_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.14283\/jpad.2018.23_bib16","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The evolution of preclinical Alzheimer's disease: implications for prevention trials","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"issue":"1","key":"10.14283\/jpad.2018.23_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"issue":"3","key":"10.14283\/jpad.2018.23_bib18","first-page":"164","article-title":"Combination Therapy of Anti-Tau and Anti-Amyloid Drugs for Disease Modification in Early-stage Alzheimer's Disease: Socio-economic Considerations Modeled on Treatments for Tuberculosis, HIV\/AIDS and Breast Cancer","volume":"3","author":"Tomaszewski","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2018.23_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jalz.2016.12.006","article-title":"Calcium Hypothesis of Alzheimer's disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis","volume":"13","author":"Alzheimer's Association Calcium Hypothesis","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.14283\/jpad.2018.23_bib20","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1096\/fj.201601221R","article-title":"Multicellular hypothesis for the pathogenesis of Alzheimer's disease","volume":"31","author":"Goetzl","year":"2017","journal-title":"FASEB J."},{"issue":"3","key":"10.14283\/jpad.2018.23_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","article-title":"The revitalized tau hypothesis on Alzheimer's disease","volume":"41","author":"Maccioni","year":"2010","journal-title":"Arch Med Res"},{"issue":"3","key":"10.14283\/jpad.2018.23_bib22","first-page":"181","article-title":"The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations","volume":"1","author":"Cavedo","year":"2014","journal-title":"J Prev Alzheimers Dis"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:53:56Z","timestamp":1736470436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724005582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S2274580724005582"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2018.23","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2018.23","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}